ADVANCED ENERGY INDUSTRIES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ADVANCED ENERGY INDUSTRIES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $327.40M | Feb 24, 2017 |
| FY2016 | Dec 31, 2015 | $268.26M | Feb 24, 2017 |
| FY2016 | Dec 31, 2014 | $230.84M | Feb 24, 2017 |
| FY2015 | Dec 31, 2013 | $169.36M | Feb 25, 2016 |
| FY2014 | Dec 31, 2012 | $322.85M | Feb 26, 2015 |
| FY2013 | Dec 31, 2011 | $338.34M | Mar 3, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.80B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.48B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $1.66B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $1.85B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $1.46B | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $1.42B | Feb 17, 2023 |
| FY2019 | Dec 31, 2019 | $338.27M | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | $175.13M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | $134.81M | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | $140.74M | Mar 2, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $135.34M | Feb 24, 2017 |
| FY2016 | Sep 30, 2016 | $126.55M | Feb 24, 2017 |
| FY2016 | Jun 30, 2016 | $118.77M | Feb 24, 2017 |
| FY2016 | Mar 31, 2016 | $103.04M | Feb 24, 2017 |
| FY2016 | Dec 31, 2015 | $86.89M | Feb 24, 2017 |
| FY2016 | Sep 30, 2015 | $109.76M | Feb 24, 2017 |
| FY2016 | Jun 30, 2015 | $108.65M | Feb 24, 2017 |
| FY2016 | Mar 31, 2015 | $109.51M | Feb 24, 2017 |
| FY2015 | Dec 31, 2014 | $110.16M | Feb 25, 2016 |
| FY2015 | Sep 30, 2014 | $91.58M | Feb 25, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $677.40M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $529.30M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $592.40M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $675.51M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $532.32M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $541.87M | Feb 17, 2023 |
| FY2019 | Dec 31, 2019 | $112.30M | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | $73.49M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | $64.13M | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | $65.74M | Mar 2, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $54.21M | Feb 18, 2025 |
| FY2024 | Dec 31, 2023 | $128.28M | Feb 18, 2025 |
| FY2024 | Dec 31, 2022 | $199.66M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $134.74M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $134.68M | Feb 17, 2023 |
| FY2019 | Dec 31, 2019 | $10.26M | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | $7.62M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | $31.69M | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | $15.37M | Mar 2, 2020 |
| FY2019 | Dec 31, 2018 | $19.41M | Mar 2, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $168.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $36.60M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $113.70M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $233.10M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $151.68M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $176.02M | Feb 17, 2023 |
| FY2019 | Dec 31, 2019 | $22.20M | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | $9.39M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | $11.01M | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | $11.79M | Mar 2, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $232.40M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $211.80M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $202.40M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $191.02M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $161.83M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $143.96M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $101.50M | Mar 16, 2022 |
| FY2020 | Dec 31, 2018 | $76.01M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $58.00M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $44.45M | Feb 21, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $242.40M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $224.60M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $221.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $218.46M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $192.00M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $188.59M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $142.56M | Mar 16, 2022 |
| FY2020 | Dec 31, 2018 | $108.03M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $93.26M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $77.68M | Feb 21, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $233.30M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $130.80M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $208.90M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $183.59M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $140.25M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $201.24M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $48.39M | Mar 16, 2022 |
| FY2020 | Dec 31, 2018 | $151.27M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $182.70M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $119.29M | Feb 21, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $107.40M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $56.80M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $61.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $58.89M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $28.82M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $36.36M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $25.19M | Mar 16, 2022 |
| FY2020 | Dec 31, 2018 | $20.33M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $9.04M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $6.82M | Feb 21, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.55B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.26B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $2.56B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $1.99B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $1.82B | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.65B | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $1.53B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $816.48M | Mar 2, 2020 |
| FY2018 | Jan 1, 2018 | $767.91M | Feb 21, 2019 |
| FY2018 | Dec 31, 2017 | $733.31M | Feb 21, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.18B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.06B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.41B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $925.90M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $945.84M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $832.32M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $855.15M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $209.18M | Mar 2, 2020 |
| FY2018 | Jan 1, 2018 | $214.73M | Feb 21, 2019 |
| FY2018 | Dec 31, 2017 | $212.67M | Feb 21, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.36B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.20B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $1.14B | Feb 13, 2026 |
| FY2025 | Dec 31, 2022 | $1.07B | Feb 13, 2026 |
| FY2022 | Dec 31, 2021 | $870.85M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $814.74M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $676.71M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $606.79M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $520.64M | Feb 21, 2019 |
| FY2016 | Dec 31, 2016 | $392.07M | Feb 24, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $300.80M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $296.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $283.80M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $281.43M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $212.19M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $209.98M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $202.93M | Mar 16, 2022 |
| FY2020 | Dec 31, 2018 | $101.90M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $53.81M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $42.13M | Feb 21, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.13B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.03B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $989.73M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $915.27M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $756.32M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $712.30M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $577.72M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $512.78M | Mar 2, 2020 |
| FY2018 | Jan 1, 2018 | $365.76M | Feb 21, 2019 |
| FY2018 | Dec 31, 2017 | $333.23M | Feb 21, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $791.20M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $722.10M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.04B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $458.82M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $544.37M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $480.37M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $346.44M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $349.30M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $407.28M | Feb 21, 2019 |
| FY2018 | Dec 31, 2016 | $281.95M | Feb 21, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $567.50M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $564.70M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $915.68M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $373.26M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $392.73M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $322.05M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $339.03M | Feb 24, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 5 | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | 3 | Feb 17, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 2, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 5 | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | 3 | Feb 17, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 2, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 37.80M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 37.70M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | 37.32M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | 37.43M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | 37.59M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | 38.29M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | 38.36M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | 38.16M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 39.60M | Feb 21, 2019 |
| FY2018 | Dec 31, 2016 | 39.71M | Feb 21, 2019 |